Fred M. Teskin

Array ( [id] => 10162570 [patent_doc_number] => 09193788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-24 [patent_title] => 'Anti-IL-17A antibodies and their uses' [patent_app_type] => utility [patent_app_number] => 14/174942 [patent_app_country] => US [patent_app_date] => 2014-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 38 [patent_no_of_words] => 59279 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14174942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480495 [patent_doc_number] => 09587026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Anti-interleukin-4 receptor antibodies' [patent_app_type] => utility [patent_app_number] => 14/175943 [patent_app_country] => US [patent_app_date] => 2014-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 26136 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14175943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10477491 [patent_doc_number] => 20150362508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'EFFECTOR T CELL RSISTANCE' [patent_app_type] => utility [patent_app_number] => 14/764899 [patent_app_country] => US [patent_app_date] => 2014-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 12208 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14764899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9560619 [patent_doc_number] => 20140178333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29' [patent_app_type] => utility [patent_app_number] => 14/165915 [patent_app_country] => US [patent_app_date] => 2014-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46245 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14165915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10483314 [patent_doc_number] => 20150368333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-24 [patent_title] => 'TNF-ALPHA ANTIGEN-BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/762948 [patent_app_country] => US [patent_app_date] => 2014-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 28486 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14762948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10477476 [patent_doc_number] => 20150362493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/761690 [patent_app_country] => US [patent_app_date] => 2014-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 30675 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14761690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9596729 [patent_doc_number] => 20140193410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein' [patent_app_type] => utility [patent_app_number] => 14/151497 [patent_app_country] => US [patent_app_date] => 2014-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 32935 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14151497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11297839 [patent_doc_number] => 09505836 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-29 [patent_title] => 'Interleukin-10 peptides and antibodies thereof for inhibiting adverse effects of protozoan infection' [patent_app_type] => utility [patent_app_number] => 14/150354 [patent_app_country] => US [patent_app_date] => 2014-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6840 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14150354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10574160 [patent_doc_number] => 09296786 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-29 [patent_title] => 'Shortened secreted polypeptides' [patent_app_type] => utility [patent_app_number] => 14/146237 [patent_app_country] => US [patent_app_date] => 2014-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 25532 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14146237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11536931 [patent_doc_number] => 09611326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-04 [patent_title] => 'Interleukin-6 receptor binding polypeptides' [patent_app_type] => utility [patent_app_number] => 14/143022 [patent_app_country] => US [patent_app_date] => 2013-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 70 [patent_no_of_words] => 82247 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14143022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756252 [patent_doc_number] => 20140286953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'HEPCIDIN, HEPCIDIN ANTAGONISTS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/103351 [patent_app_country] => US [patent_app_date] => 2013-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 58918 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14103351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10684381 [patent_doc_number] => 20160030526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'Bivalent IL-2 Fusion Toxins' [patent_app_type] => utility [patent_app_number] => 14/650699 [patent_app_country] => US [patent_app_date] => 2013-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 20154 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14650699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9772824 [patent_doc_number] => 20140296487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses' [patent_app_type] => utility [patent_app_number] => 14/088328 [patent_app_country] => US [patent_app_date] => 2013-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 84202 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14088328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9698956 [patent_doc_number] => 20140248641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-04 [patent_title] => 'CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS' [patent_app_type] => utility [patent_app_number] => 14/068992 [patent_app_country] => US [patent_app_date] => 2013-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13243 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14068992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10649415 [patent_doc_number] => 09365652 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-14 [patent_title] => 'Use of IL-20 antagonists for treating liver diseases' [patent_app_type] => utility [patent_app_number] => 14/067034 [patent_app_country] => US [patent_app_date] => 2013-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 21572 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14067034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10381955 [patent_doc_number] => 20150266962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'ANTI-IL-13 RECEPTOR ALPHA 2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/439897 [patent_app_country] => US [patent_app_date] => 2013-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21327 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14439897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10090254 [patent_doc_number] => 09127067 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-08 [patent_title] => 'Methods of treatment using chemokine receptor binding polypeptides' [patent_app_type] => utility [patent_app_number] => 14/065679 [patent_app_country] => US [patent_app_date] => 2013-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 73118 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14065679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700540 [patent_doc_number] => 20160046687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS RELATED THERETO' [patent_app_type] => utility [patent_app_number] => 14/436491 [patent_app_country] => US [patent_app_date] => 2013-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 25288 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14436491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9268743 [patent_doc_number] => 20140023660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-23 [patent_title] => 'Anti-IL 13 Human Antibodies' [patent_app_type] => utility [patent_app_number] => 14/044314 [patent_app_country] => US [patent_app_date] => 2013-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25722 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14044314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10129256 [patent_doc_number] => 09163082 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-20 [patent_title] => 'Methods for the treatment of IL-1β related diseases' [patent_app_type] => utility [patent_app_number] => 14/042205 [patent_app_country] => US [patent_app_date] => 2013-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 38452 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14042205 [rel_patent_id] =>[rel_patent_doc_number] =>)